Profound Medical Corp. (NASDAQ:PROF) announced today preliminary unaudited revenue for the third quarter ended September 30, 2025, reporting total sales of $5.2 million to $5.3 million—an 84‑87% increase over the $2.8 million earned in the same period a year earlier. Gross margin for the quarter is expected to be 72%, up from 64% in the prior year period. The company’s CEO, Arun Menawat, highlighted that the growth was driven by both new system installations and higher utilization of existing equipment.
The company’s installed base expanded to 67 TULSA‑PRO systems from 60 at the end of the second quarter, with Menawat noting a strong capital‑sales pipeline that should bring the total to at least 75 installations by year‑end. The announcement also reiterated Profound’s focus on expanding its market through the TULSA‑AI BPH module and the TULSA Plus program, which are expected to broaden the addressable prostate disease market. The company’s financial outlook remains positive, with a projected gross margin improvement and continued revenue acceleration.
Profound will release its full third‑quarter 2025 financial results on Thursday, November 13, 2025, and will host a conference call at 4:30 p.m. ET to discuss the results and business developments. The company’s preliminary data suggest a strong trajectory for the remainder of the fiscal year, reinforcing its guidance for 70‑75% revenue growth in 2025 and positioning it for triple‑digit expansion in 2026 and beyond.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.